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Immune-suppressive cell populations impair antitumor immunity and can contribute 
to the failure of immune therapeutic approaches. We hypothesized that the non-
steroidal anti-inflammatory drug licofelone, a dual cyclooxygenase-2/5-LO inhibitor, 
would improve therapeutic melanoma vaccination by reducing immune-suppressive 
cell populations. Therefore, licofelone was administered after tumor implantation, either 
alone or in combination with a peptide vaccine containing a long tyrosinase-related 
protein 2-peptide and the adjuvant α-galactosylceramide, all formulated into cationic 
liposomes. Mice immunized with the long-peptide vaccine and licofelone showed 
delayed tumor growth compared to mice given the vaccine alone. This protection 
was associated with a lower frequency of immature myeloid cells (IMCs) in the bone 
marrow (BM) and spleen of tumor-inoculated mice. When investigating the effect of 
licofelone on IMCs in vitro, we found that the prostaglandin E2-induced generation of 
IMCs was decreased in the presence of licofelone. Furthermore, pre-incubation of BM 
cells differentiated under IMC-inducing conditions with licofelone reduced the secretion 
of cytokines interleukin (IL)-10 and -6 upon lipopolysaccharides (LPS) stimulation as 
compared to untreated cells. Interestingly, licofelone increased IL-6 and IL-10 secretion 
when administered after the LPS stimulus, demonstrating an environment-dependent 
effect of licofelone. Our findings support the use of licofelone to reduce tumor-promoting 
cell populations.
Keywords: cancer vaccine, melanoma, nsaiD, cOX-2/5-lO, myeloid-derived suppressor cells, immature myeloid 
cells, liposomes, α-galactosylceramide
inTrODUcTiOn
Successful cancer vaccines not only need to stimulate a robust antitumor immune response, but 
also need to alleviate the effects of immune-suppressive cell populations (1). Inflammatory factors 
secreted by tumor cells can polarize stromal and immune cells, including macrophages, immature 
myeloid cells (IMCs) [also known as myeloid-derived suppressor cells (MDSCs)], and T-cells, 
toward an immune-suppressive phenotype (2). Furthermore, the constant secretion of inflamma-
tory molecules by tumor cells into the systemic circulation promotes IMCs to egress from the bone 
marrow (BM) and to infiltrate the tumor where they suppress antitumor immunity (3). IMCs have 
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been identified as one of the major pro-tumor immune popula-
tions and are positively correlated with melanoma progression, 
which makes them an attractive target for immunotherapy (4, 5).
Immature myeloid cells are a heterogeneous population of 
myeloid precursor cells that are present in most cancers and 
which typically expand during disease progression (3). IMCs 
are induced by tumor-derived inflammatory factors [e.g., VEGF, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), 
prostaglandins, interleukin (IL)-1β, IL-6, IL-10, TGF-β, 
S100A8, and S100A9] (2, 6, 7) that stimulate tumor growth and 
myelopoiesis and block the differentiation of IMCs into mature 
effector cells such as DCs, macrophages, and granulocytes 
(8, 9). In mouse models, IMCs can be divided into distinct 
subpopulations based on cell morphology and the expression 
of the cell surface markers Gr-1 and CD11b, as well as by their 
suppressive functions (10). The suppressive ability of monocytic 
IMCs (CD11b+ Gr-1intermediate) is mediated through an increased 
catabolism of the essential amino acid arginine, which results 
in decreased proliferation, anergy, and increased apoptosis of 
T-cells (2). Granulocytic IMCs (CD11b+ Gr-1high) produce large 
amounts of reactive oxygen species (ROS) that impede T-cell 
receptor signaling (10). Activated IMCs can themselves produce 
pro-inflammatory stimuli such as IL-6, prostaglandin E2 (PGE2), 
and VEGF, which provide a positive feedback loop for their 
recruitment and activation (8).
One of the key inflammatory factors closely linked to carcino-
genesis as well as to the induction, accumulation, and activation 
of IMCs is PGE2 (11). PGE2 is a physiologically abundant eicosa-
noid, derived from arachidonic acid through the cyclooxygenase 
(COX)-1 and -2 enzymatic pathways (12). PGE2 synergizes 
with leukotriene B4 (LTB4) to induce local inflammation and to 
attract immune cells into tissue (13). Leukotrienes (LTs) are also 
produced from arachidonic acid but require the enzyme 5-lipoxy-
genase (5-LO) for the production of inflammatory mediators 
(14). 5-LO expression is detectable in granulocytes, monocytes, 
and macrophages, which produce the largest quantities of LTs, 
while expression in DCs, B-cells, and mast cells is lower (15). In 
contrast to COX-1, which is constitutively expressed in almost 
all tissues, the expression of COX-2 is tightly regulated. Apart 
from constitutive expression in the brain and kidneys, COX-2 
expression in other tissues is low but can rapidly be induced 
by inflammatory factors (16). Furthermore, overexpression of 
COX-2 has been observed in many cancers (13).
Recently, blockade of PGE2 using the non-steroidal anti-
inflammatory drug (NSAID), celecoxib (a specific COX-2 
inhibitor), was shown to improve immunotherapy by inhibiting 
the generation of IMCs (17). Similarly, the blockage of LTB4-
mediated effects improved antitumor immunity in a mouse 
model (18). Since COX-2 and 5-LO convert the same substrate, 
inhibition of either of these pathways frees up arachidonic acid 
that can be used by the other enzyme, therefore simultaneous 
inhibition of both enzymes could offer superior anti-inflamma-
tory effects combined with a better safety profile (19). To date, 
several NSAIDs with dual COX-2/5-LO activity have undergone 
clinical testing for use in the treatment of inflammatory diseases, 
with licofelone (2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-
5,7-dihydropyrrolizin-3-yl]acetic acid) being the most advanced. 
In addition to demonstrating an excellent tolerability, licofelone 
has been shown to have a dose-dependent anticancer effect in 
cell culture and in animal models (20–22). So far studies have 
focused on the ability of licofelone to directly inhibit PG (21) and 
LT synthesis (23) and induce apoptosis in tumor cells; however, 
little is known about its direct effects on immune cell populations 
in the context of cancer.
We hypothesized that a combination therapy utilizing the 
NSAID licofelone along with a therapeutic cancer vaccine 
would decrease inflammatory signaling through COX-2/5-LO 
inhibition in immune cells and thus facilitate the development 
of antitumor immunity. To test this hypothesis, licofelone was 
administered to mice following implantation of tumor cells and 
was incorporated into a therapeutic liposomal cancer vaccine 
containing a long peptide and the adjuvant α-galactosylceramide 
(α-GalCer), previously shown to increase tumor survival in a 
melanoma model (24). Immunization with long peptides con-
taining both a CD4 and CD8 T-cell epitope induce improved 
immune responses as compared to minimal T-cell epitopes, 
which do not require processing prior to presentation on MHC 
molecules and can induce tolerance (25, 26). The combination 
of a long peptide [tyrosinase-related protein (TRP) 2], the 
adjuvant α-GalCer, and licofelone prolonged the survival 
of tumor-bearing mice as compared to the TRP2–α-GalCer 
vaccine alone. Further, we show that the prolonged survival 
correlated with a decrease in the number of IMCs in tumor-
bearing mice. Further investigation of the effects of licofelone 
on IMCs in  vitro demonstrated changes in IMC phenotype 
including their ability to produce pro-inflammatory cytokines. 
These findings support the use of licofelone as an additional 
component in cancer vaccination regimens, enhancing their 
immunotherapeutic potential.
MaTerials anD MeThODs
Materials
Lipopolysaccharides (LPS from Escherichia coli 055:B5), colla-
genase from Clostridium histolyticum Type IA, phosphatidylcho-
line (PC), 2′,7′-dichlorofluorescin diacetate (DCFDA), and PGE2 
were purchased from Sigma Aldrich, USA. Murine IL-6 and -10 
CBA flex set were purchased from BD Bioscience, USA. Murine 
GM-CSF was purchased from Biolegend, New Zealand. The 
lipids 1,2-dioleoyl-3-trimethylammonium-propane (chloride 
salt) (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethan-
olamine (DOPE) were bought from Avanti Polar Lipids, USA. 
α-GalCer, synthesized from galactose and phytosphingosine, 
TCI P1765, via α-specific glycosylation methodology (27), was 
kindly provided by Gavin Painter, Ferrier Research Institute, 
New Zealand. The long TRP2-peptide [TRP2(180–188),(88–102)-
SVYDFFVWLKFFHRTCKCTGNFA] and the CD4 and CD8 
OVA peptides (ISQAVHAAHAEINEAGR and SIINFEKL, 
respectively) were purchased from Mimotopes, Australia. 
B16F10luc2 melanoma cells were obtained from ATCC, New 
Zealand. Licofelone was from AdooQ Bioscience, CA, USA. 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) was 
purchased from Molecular Probes, USA. CD43 microbeads were 
from Miltenyi Biotec, Germany.
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Preparation and characterization of 
cationic liposomes
Cationic liposomes containing the long TRP2-peptide and 
αGalCer were prepared by hydrating thin lipid films as described 
previously (24). For some formulations, 4.43 mg licofelone was 
added to the lipid precursor prior to hydration. All liposomal 
formulations were diluted with sterile PBS in order to deliver 
200 ng/mouse α-GalCer, 20 nmol/mouse long TRP2-peptide, and 
5 mg/kg licofelone per injection. Cationic liposomes containing 
only 5  mg/kg licofelone were similarly prepared. Particle size 
(Z-average) and polydispersity (PDI) of the preparations were 
analyzed by photon correlation spectroscopy. Electrophoretic 
mobility was measured in order to determine the zeta potential 
of the formulations. Results are the average of three independent 
samples measured in triplicate at 25°C.
Mice
The 6- to 10-week-old C57BL/6J and OT-I mice were bred and 
maintained under specific pathogen-free conditions at the HTRU, 
University of Otago. The Animal Ethics Committee, University of 
Otago, approved all experiments (AEC 16/14).
Tumor challenge
B16F10luc2 melanoma cells (1 × 105 cells) were injected subcu-
taneously into the right flank C57BL/6 mice and tumor growth 
and body weight were monitored every 2 days. Tumor size was 
assessed by measuring the length and the width of the tumor 
using digital calipers and mice were culled when tumors reached 
predetermined humane end points or at 20  days post-tumor 
injection.
immunization schedule
B16F10luc2 melanoma-bearing mice were randomly divided 
into five groups of seven mice each and were left untreated or 
were injected intravenously on day 6 with vaccine (TRP2-peptide 
and α-GalCer in cationic liposomes) or licofelone-vaccine 
(TRP2-peptide, α-GalCer, and licofelone in cationic liposomes) 
plus additional licofelone in cationic liposomes or with only 
the licofelone liposomes (no vaccine). The licofelone liposomes 
were given by subcutaneous injection in the neck once every 
second day, starting on the day of tumor grafting until day 14 
of the study.
Phenotyping of immune subsets after 
Tumor challenges
Mice were sacrificed 20  days after tumor cell injection and 
single cell suspensions were prepared from the tumor-draining 
lymph nodes (td-LNs), spleens, and one hind limb (for the 
recovery of BM cells). BM was extracted from the hind limbs 
as described previously (24). The cells were re-suspended at 
1 ×  106  cells/mL and incubated with the following antibodies 
after non-specific binding was blocked by incubation with Fc 
receptor block (F16/32): CD11b PE-Cy7, Gr-1 FITC, CD11c 
APC, F4/80 brilliant violet 421, and CD3 APC-Cy7 (all anti-
bodies were purchased from Biolegend, New Zealand and were 
titrated on splenocytes and BM cells). Propidium iodide (PI) 
was added prior to acquiring data using a BD FACSCanto II 
and FlowJo software (version 9.5.2, TreeStar, Inc., USA) was 
used to analyze data.
Viability and rOs Production  
of Ex Vivo-Derived Melanoma cells
Macerated tumors from C57BL/6 mice were incubated with col-
lagenase from C. histolyticum Type IA (1 mg/mL) and calcium 
chloride (44.1 μg/mL) at 37°C for 30 min. Red blood cells were 
lysed and the tumor cells were re-suspended at 5 × 105 cells/mL 
in cIMDM and seeded into a 24 well plate. These cells were incu-
bated with increasing doses of licofelone (1–20 μM) for 48 h and 
viability and ROS production were examined by flow cytometry 
after incubation with PI and 1 μL of freshly prepared DCFDA 
(10 μM stock solution).
generation and Phenotyping of iMcs
Bone marrow cells were isolated from naïve C57BL/6 mice as 
described previously (28, 29) and seeded at 5 ×  105  cells/mL 
in the presence of GM-CSF (20  ng/mL) and PGE2 (9.1  μg/
mL). Increasing concentrations of licofelone (2.5–50 μM) were 
added to the culture and refreshed every other day (11) together 
with media and cytokines. Cells were harvested on day 5 of 
culture and the phenotype analyzed. In some experiments, BM 
cells harvested from tumor-bearing mice and were re-cultured 
for 24 h in the presence of either licofelone (5 μM), LPS (50 ng/
mL), or a combination of both. Culture supernatants were 
stored at −20°C for subsequent cytokine analysis using BD 
Biosciences CBA Mouse Flex Sets. Samples were run on a BD 
FACSCanto II and the FCAP Array software (v1.0, Soft Flow) 
was used to calculate cytokine concentrations in the samples 
and the standards.
T-cell suppression assay
The suppressive potential of IMCs was evaluated by their ability 
to inhibit antigen-specific T-cell proliferation. To prepare target 
T-cells, spleens were dissected from naive OT-I mice and CD43+ 
cells were isolated by positive selection on an AutoMACS Pro 
Separator (Miltenyi Biotec) to exclude B-cells. CFSE labeled 
(24) CD43+ splenocytes were seeded at 5 ×  104  cells/well in 
a 96 well round-bottom plate and stimulated with the CD8 
epitope of ovalbumin (SIINFEKL; 0.01 μg/mL) in the presence 
or absence of IMCs for 48 h. IMCs were generated in vitro as 
described above and incubated with licofelone (5 μM) for 20 h 
before LPS (50 ng/mL) was added for 4 h. Cells were washed, re-
suspended, and added to the sorted splenocytes at the indicated 
ratios. After 48  h the proliferation of T-cells was assessed by 
flow cytometry.
statistical analysis
The statistical significance between values was compared using 
one-way ANOVA followed by post hoc Tukey’s pairwise compari-
son. All data are expressed as the mean + SD. Survival curves were 
compared by using the Log-rank test (Mantel–Cox). Statistical 
analysis was performed using GraphPad Prism version 6.00. All 
experiments were repeated at least twice.
FigUre 1 | addition of licofelone to a long-peptide cancer vaccine therapy prolongs survival of melanoma-bearing mice. Groups of mice (n = 7) were 
injected s.c. with 5 × 104 B16F10luc2 tumor cells and were subsequently left untreated or injected i.v. on day 6 with TRP2-peptide and α-GalCer in cationic 
liposomes or TRP2-peptide, α-GalCer, and licofelone in cationic liposomes. Mice that received a vaccine containing licofelone in cationic liposomes were also 
injected s.c. every second day with the licofelone formulated into cationic liposomes while a control group of mice received only s.c. injections of licofelone 
liposomes. The graph shows the Kaplan–Meier survival curve. Data are representative of two independent experiments with each n = 7 mice/group, ***p < 0.0001.
Table 1 | Overview of average particle size, PDi index, and zeta potential 
of vaccine formulations.
cationic liposomes 
containing
Z-average  
(nm)
PDi Zeta  
potential (mv)
Long TRP2-peptide +  
α-GalCer
280 ± 87 0.34 ± 0.2 43.6 ± 0.8
Long TRP2-peptide +  
α-GalCer + licofelone
226 ± 43 0.25 ± 0.1 42.5 ± 2.6
Licofelone 802 ± 59 0.33 ± 0.1 39.9 ± 14.5
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resUlTs
incorporation of the nsaiD licofelone into 
Therapeutic cancer Vaccine regimens 
improves survival of Tumor-bearing Mice
We have recently shown that a therapeutic vaccine, consisting 
of a long TRP2-peptide co-delivered with α-GalCer in cationic 
liposomes, increased cytotoxic T-cell responses, and improved 
tumor survival in melanoma-bearing mice (24). To investigate 
if the antitumor efficacy of the vaccine could be enhanced, the 
dual COX-2/5-LO inhibitor licofelone was added to the therapy. 
Licofelone was included as part of the vaccine and was also deliv-
ered by subcutaneous injection pre- and postimmunization, as 
we hypothesized that this would allow enhanced T-cell priming.
We characterized the cationic liposomes containing the 
long TRP2-peptide, α-GalCer ± licofelone regarding their size, 
PDI, and zeta potential as the size and charge of liposomes 
influences their immunogenicity (25). Cationic liposomes 
containing the long TRP2-peptide and α-GalCer displayed a size 
of 280 ± 87 nm and a positive surface charge of 43.6 ± 0.8 mV 
(Table  1). Incorporation of licofelone into cationic liposomes, 
together with the TRP2-peptide and α-GalCer, did not markedly 
alter the size (243 ±  43  nm) or surface charge of the cationic 
liposomes. However, liposomes containing only licofelone alone 
were significantly larger (802 ± 59 nm, p < 0.001).
Tumor-bearing mice were treated i.v. with the liposomal vac-
cine containing the long TRP2-peptide, α-GalCer ± licofelone, or 
with liposomal licofelone alone. In addition, groups immunized 
i.v. with the vaccine containing licofelone, or liposomal licofelone 
alone, received repeated s.c. injections of liposomal licofelone. 
Immunization with the long TRP2-peptide vaccine prolonged 
the survival of melanoma-bearing mice compared to untreated 
mice, with the best outcome being seen when mice were also 
given licofelone. Vaccination with the combination of long TRP2-
peptide vaccine and licofelone resulted in 5/7 (71.4%) of the vac-
cinated mice remaining tumor free (p < 0.01) (Figure 1). Mice 
injected with licofelone had the same survival times as untreated 
mice. No adverse effects were observed with vaccine treatments, 
as indicated by steady body weight over the vaccine treatment 
period (data not shown).
Treatment with licofelone-containing 
Vaccine Decreases gr-1+ cD11b+ cell 
Population in Tumor-inoculated Mice
We hypothesized that the addition of licofelone prolonged the 
survival of tumor-bearing mice by reducing the frequency of 
immune-suppressive populations in lymphatic organs. Therefore, 
we examined the frequency of myeloid cell populations in the 
BM, spleen, and td-LNs 20  days after tumor inoculation. 
Tumor-inoculated mice treated with i.v. licofelone-vaccine plus 
additional s.c. licofelone showed a decrease in the frequency of 
Gr-1− F4/80+ macrophages and CD11c+ cells in spleen and, for 
Gr-1− F4/80+ macrophages, in BM (Figure  2). Examination of 
myeloid subsets in the td-LNs showed a trend toward a reduced 
frequency of Gr-1+ CD11b+ IMCs in mice treated with any of the 
three formulations; however, this was not significant.
The frequency of Gr-1+ CD11b+ IMCs in the BM and the 
spleen was reduced in mice treated with either the i.v. vaccine 
or the i.v. licofelone-vaccine plus additional s.c. licofelone. In 
addition, the frequency of Gr-1+ CD11b+ IMCs in spleen was 
reduced after licofelone treatment alone (i.v. licofelone plus s.c. 
FigUre 2 | addition of licofelone to the vaccine therapy reduces the frequency of myeloid cell populations in the bM and the spleens of tumor-
bearing mice. Mice were manipulated as described in Figure 1 and the BM, spleens, and td-LNs were collected on day 20 and analyzed for the frequency of 
(a) Gr-1− F4/80+ macrophages, (b) Gr-1+ CD11b+ IMCs, and (c) CD11c+ DCs by flow cytometry. Frequencies are shown as a percentage of live cells (PIlow cells). 
Data shown are the mean ± SD of five to seven mice from two experiments. ***p < 0.001, **p < 0.05, *p < 0.01.
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licofelone), without vaccination with the long TRP2-peptide and 
α-GalCer. No significant changes were observed in the frequency 
of CD4+ and CD8+ T-cell populations (data not shown).
licofelone Does not inhibit Melanoma 
cell growth and rOs Production In Vitro
In order to examine if the antitumor effect of licofelone observed 
in  vivo was attributable to a direct inhibition of tumor cell 
growth, we evaluated the viability of B16F10luc2 melanoma 
cells, derived ex vivo, after a 48-h incubation with licofelone. 
No  significant reduction in viability was observed after incu-
bation of B16F10luc2 melanoma cells harvested from tumor-
bearing mice with licofelone at 1, 5, 10, or 20 μM (Figure 3A). 
Similarly, the production of ROS by melanoma cells, as meas-
ured by DCFDA staining, was not changed after treatment with 
licofelone (Figure 3B).
FigUre 3 | Viability (a) and rOs production (b) of melanoma cells 
derived ex vivo are not changed by licofelone treatment. B16F10luc2 
melanoma cells were treated with licofelone at 1, 5, 10, or 20 μM for 48 h. 
Data shown are the mean + SD from three individual experiments.
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Treatment of gr-1+ cD11b+ iMcs with 
licofelone reduces the Production of il-6 
and -10 in a Time-Dependent Manner
Increased generation of IMCs in the BM and subsequent accu-
mulation within the tumor has been associated with cancer 
progression (30). Since licofelone affected the phenotype of BM 
cells differentiated in the presence of inflammatory mediators 
associated with tumor progression, we examined if licofelone 
also influenced the secretion of pro-inflammatory cytokines by 
IMCs. IL-6 and IL-10 are important inflammatory mediators 
involved in Gr-1+ CD11b+ mediated immune suppression. The 
levels of these two cytokines were analyzed in PGE2 and GM-CSF 
differentiated BM cultures treated either with licofelone (5 μM) 
and/or LPS (50 ng/mL). LPS was added to activate the cells and 
induce cytokine production.
While concentrations of IL-6 increased when licofelone was 
added to the cultures for as little as 4  h after LPS activation 
(Figure  4A), the treatment of cells with licofelone and LPS 
only resulted in a significant increase in IL-10 when cultures 
were supplemented with licofelone for 20 h after LPS activation 
(Figure 4B). The reduced levels of IL-10 measured at 24 h may be 
due to autocrine IL-10 uptake as blocking uptake with anti-IL-10 
receptor antibodies has shown to increase the amount of IL-10 
detected in culture (31).
The reverse experiment was also carried out whereby the BM 
cells differentiated under IMC-inducing conditions were pre-
incubated with licofelone before the addition of LPS for 4–20 h. 
Control levels of cytokine in LPS-stimulated cells were measured 
to assess the effect of licofelone pre-incubation. Treatment of 
cells with licofelone for 4 h prior to the addition of LPS (for the 
remaining 20 h) completely ablated the production of IL-6 and 
IL-10 (Figures  4C,D). Cells stimulated with LPS at later time 
points did not result in a decrease in amounts of both IL-6 and 
IL-10 produced.
licofelone suppresses the generation 
of gr-1+ cD11b+ iMcs and gr-1− F4/80+ 
Macrophages In Vitro
The COX-2 inhibitor celecoxib (32) and several E-prostanoid 
receptor antagonists (11) have been shown to modulate the 
generation and the suppressive potential of IMCs. To investigate 
if the dual COX-2/5-LO inhibitor licofelone shapes myeloid cell 
populations, BM cells were cultured in the presence of inflamma-
tory factors (PGE2 and GM-CSF) commonly secreted by tumor 
cells (11) and increasing doses of licofelone. The generation of 
Gr-1+ CD11b+ IMCs was significantly suppressed in the presence 
of 2.5 and 5 μM licofelone while the generation of Gr-1− F4/80+ 
macrophages was suppressed with all three concentrations of 
licofelone used (Figure  5). The addition of licofelone had no 
impact on the generation of CD11c+ cells.
licofelone attenuates the suppressive 
Function of gr-1+ cD11b+ iMcs
Next, we examined if licofelone was able to ameliorate or reverse 
the suppressive function of CD11b+ Gr-1+ IMCs in vitro. CD11b+ 
Gr-1+ IMCs were generated in  vitro from BM precursor cells, 
pulsed with the SIINFEKL peptide, and activated with LPS prior 
to coculture with OT-I mouse splenocytes. The proliferation of 
T-cells was suppressed at all investigated ratios with licofelone 
being able to reverse the suppressive function of CD11b+ Gr-1+ 
IMCs partially (Figure 6).
DiscUssiOn
One of the biggest obstacles preventing the success of cancer vac-
cines is the ability of tumor cells to evade killing by the immune 
system. This is facilitated by the development of immune-sup-
pressive cell populations in the BM, which subsequently migrate 
to the tumor. Here we investigated the potential of the NSAID 
licofelone, a dual COX-2/5-LO inhibitor, to reduce the frequency 
of immune-suppressive cells in lymphatic organs and to stimulate 
antitumor immunity when used in combination with a cancer 
vaccine. Licofelone was administered in two ways, once i.v. on 
day 6 after tumor grafting with the other vaccine components 
(long TRP2-peptide and α-GalCer) in cationic liposomes, and 
also every second day s.c. over a period of 14  days beginning 
on the day of the tumor grafting, again formulated into cationic 
liposomes.
FigUre 4 | licofelone increases il-6 (a,c) and il-10 (b,D) production when added to lPs-stimulated cells but decreases the production of the two 
cytokines when added prior to lPs stimulation. IMCs generated from the BM of tumor-bearing mice with GM-CSF (20 ng/mL) and PGE2 (9.1 μg/mL) for 
5 days. Cells were treated either with licofelone (5 μM) and/or LPS (50 ng/mL) alone as described. Data shown are mean + SD of pooled groups from two 
independent experiments. ***p < 0.0001.
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Previous reports have described a chemo-preventive effect of 
licofelone in colon cancer (20) and lung adenoma (22, 33) models 
when administered directly to the cancer site. While in vitro low 
concentrations (2.5–40 μM) of licofelone decreased proliferation 
of several prostate tumor cell lines by inducing apoptotic cell 
death (21), at higher concentrations (150 μM) licofelone induced 
mitochondrial dysfunction (34). However, we found no effect 
of systemic licofelone monotherapy on the development of 
solid tumors in the melanoma model and no direct effect of 
licofelone on the viability of B16F10luc2 tumor cells harvested 
from tumor-bearing mice in  vitro. Similarly, licofelone did not 
influence the ROS production of B16 melanoma cells isolated 
from tumor-bearing mice. These results align with studies that 
demonstrate COX-2 independent inhibition of ROS production 
by chemo-preventive drugs, such as nitric oxide-donating aspirin, 
and suggest that these are off-target effects of the COX inhibitor 
(35). Together this indicates that in this model the NSAID needs 
to be given in combination with a vaccine in order to stimulate 
effective antitumor responses and improve survival. Experiments 
replacing licofelone with the COX-2 inhibitor celecoxib (data not 
shown) did not improve survival, suggesting that dual inhibition 
of both COX-2 and 5-LO is beneficial.
We chose to package the vaccine components and licofelone 
into cationic liposomes as they are an excellent delivery system 
for poorly water-soluble drugs, such as licofelone, and are 
inherently immune-stimulatory (36). The size and charge of the 
liposomes strongly affects their systemic distribution as well as 
the uptake and activation of APCs. The positive charge facili-
tates interactions with the negatively charged cell membranes 
and is thereby thought to enhance antigen delivery to DCs (37). 
FigUre 6 | incubation with licofelone reduces suppressive activity of 
gr-1+ cD11b+ iMcs. BM cells differentiated in the presence of GM-CSF 
(20 ng/mL) and PGE2 (9.1 μg/mL) were incubated with licofelone (5 μM) for 
20 h (gray bar) or media (black bar) and then pulsed with LPS and OVA257–264 
for 4 h before they were cocultured with CFSE-stained splenocytes from OT-I 
mice in varying ratios. After 72 h, the proliferation of OVA stimulated T-cells 
was assessed by flow cytometry. Data are representative of three 
independent experiments with two replicates + SD each, ***p < 0.0001.
FigUre 5 | licofelone affects the generation of iMcs and 
macrophages in vitro. BM cells were harvested from the femur of naive 
C57BL/6 mice and were incubated with media and GM-CSF (20 ng/mL), 
PGE2 (9.1 μg/mL), and licofelone (2.5, 5, and 10 μM) for 5 days. The 
frequency of (a) Gr-1+ CD11b+ IMCs, (b) Gr-1− F4/80+ macrophages, and 
(c) CD11c+ DCs was determined by flow cytometry. Frequencies are shown 
as a percentage of live cells (PIlow cells). The results are the mean + SD of 
three independent experiments (n = 2/experiment). ***p < 0.001, **p < 0.01, 
*p < 0.05.
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Furthermore, cationic liposomes activate pro-inflammatory and 
pro-apoptotic pathways that lead to the generation of ROS (38), 
enhanced expression of costimulatory molecules such as CD80 
and CD86, and secretion of chemokines and cytokines (39), 
which together should support the generation of an antitumor 
response. We have previously shown that immunization with 
a liposomal vaccine, with a similar size and charge as reported 
here, was superior in terms of eliciting CD8+ T-cell responses 
as compared to immunization with the vaccine components 
alone (24).
When we analyzed the composition of cells after immunization 
with the various vaccines, we detected significant differences in 
the frequency of myeloid cell populations in the spleens and BM 
of tumor-inoculated mice treated with a licofelone-containing 
vaccine with the levels of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ 
macrophages being decreased. A similar trend was observed 
in the td-LNs; however, these differences were not statistically 
significant which is likely due to variation in the size of tumors 
on the day they were harvested. The frequency of Gr-1+ CD11b+ 
IMCs was also decreased in mice treated with the vaccine alone 
(without licofelone), perhaps indicating that one of the other 
vaccine components was responsible for this change. For exam-
ple, the glycolipid α-GalCer, used as an adjuvant in this study, 
activates iNKT cells, which are known to reduce the suppressive 
potential of IMCs (40). Moreover, α-GalCer has been shown to 
promote the maturation of DCs and to contribute to the induc-
tion of T-cell responses (41). Even though vaccines containing the 
iNKT adjuvant α-GalCer improved the survival of tumor-bearing 
mice, the antitumor effect was further improved by the addition 
of licofelone to the treatment regimen, significantly extending the 
median survival time.
The effect of licofelone on myeloid cells from immunized 
tumor-inoculated mice ex vivo and directly in vitro was examined. 
An important factor to consider when interpreting the results 
from the in  vitro experiments is the phenotype of cells gener-
ated in the chosen culture conditions. Approximately 60–70% of 
BM-derived cells generated in the presence of GM-CSF express 
high levels of CD11c and MHCII and are able to stimulate 
T-cell proliferation in response to antigens (42). The addition of 
PGE2 and IL-4 has been shown to reduce the CD11c+ MHCII+ 
population and instead increases the frequency of Gr-1+ CD11b+ 
IMCs, which are able to suppress T-cell proliferation (11). In 
accordance with these studies, we found approximately half of 
our cells, cultured with GM-CSF and PGE2 for 5 days, expressed 
Gr-1 and CD11b and were able to suppress T-cell proliferation. 
The addition of licofelone at 2.5–5  μM was able to directly 
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suppress the generation of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ 
macrophages. This supports the results of the ex vivo analysis 
where the frequency of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ 
macrophages was similarly reduced after licofelone treatment. 
While there is little other published information regarding dual 
COX-2/5-LO inhibitors; the COX-2 inhibitor celecoxib, when 
used in a mesothelioma mouse model, affected both the number 
and the function of IMCs by inhibiting PGE2 synthesis and 
decreasing ROS and NO production (43). The in vitro observed 
effect of licofelone on macrophages is intriguing as cytokines pro-
duced by macrophages upon exposure to PGE2, such as IL-6, are 
important modulators of IMC function (11). Since we observed 
an effect of licofelone on both, macrophages and IMCs, it remains 
to be determined if only one of these populations or both are 
responsible for the observed antitumor immunity. However, 
the expression of the same cell surface markers by both MDSCs 
and macrophages makes it difficult to distinguish between the 
cell populations and consequently the effects of licofelone. For 
example, an immune-suppressive subset of MDSCs with a low 
expression of Gr-1 has been described and found to also express 
F4/80 (44). Since both cell populations are able to suppress T-cell 
responses, the inhibition of their development by licofelone is 
advantageous.
Reduced COX-2 and 5-LO activity has also been associated 
with a decrease in pro-inflammatory cytokines detectable in the 
serum of tumor-bearing mice. This included IL-6, which is one of 
the major cytokines involved in the expansion of Gr-1+ CD11b+ 
IMCs (20, 45). Therefore the production of IL-6 and IL-10 [which 
activates the immune-suppressive and tumor-promoting effects 
of Gr-1+ CD11b+ IMCs via STAT3 and STAT6 signaling (46–48)] 
by licofelone-treated cells differentiated under IMC-inducing 
conditions was examined. We found that licofelone treatment 
of IMC-differentiated LPS-activated cells was unable to reduce 
production of both IL-6 and IL-10 and instead increased cytokine 
production in some conditions. However, when licofelone was 
given before LPS activation, both IL-6 and IL-10 production 
was almost completely suppressed. Interestingly, the effect of 
licofelone was transient with suppression only being apparent 
when licofelone was given around the time of LPS activation. 
Blidner et  al. have shown a differential response of IMCs to 
the COX-1/2 inhibitor, indomethacin, depending on the IMC 
microenvironment (49). Under inflammatory conditions, 
associated with the tumor progression, indomethacin counter-
acted the suppressive actions of the IMCs and increased their 
expression of Gr-1. Interestingly, indomethacin treatment in a 
non-inflammatory environment led to an increase in NO and 
ROS production in IMCs, amplifying their immune suppression 
(49, 50). The changes in IL-6 and -10 production after licofelone 
treatment of LPS-stimulated and unstimulated of Gr-1+ CD11b+ 
IMCs complement these observations.
Immune suppression, the key feature of IMCs, is mediated 
through various metabolic and signaling pathways, as well as 
through direct cell-to-cell contact (8). Therefore, it was of inter-
est to see that licofelone pre-treatment of BM cells differenti-
ated under IMC-conditions could partially reverse CD8 T-cell 
suppression. This is in agreement with findings from studies 
that have found other anti-inflammatory agents, for example 
celecoxib, to reverse IMC induced T-cell suppression in vitro (32, 
43, 51). It remains to be determined if the antitumor activity 
of licofelone solely depends on the inhibition of Gr-1+ CD11b+ 
IMCs numbers and function through effects on prostaglandin 
and LT synthesis; or if other factors, such as inhibition of VEGF 
production (21), are involved. However utilizing a safe, small 
molecule drug such as licofelone to reduce tumor-induced 
immune suppression and potentiate immune responses stimu-
lated by therapeutic vaccines provides an attractive alternative to 
the use of checkpoint blockade inhibitors; which while proving 
to be very effective in some situations (52, 53) are expensive, 
cannot be delivered orally and have the potential for serious 
immune-related adverse events (53, 54).
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FigUre s1 | gating strategy for identification of iMcs harvested from 
tumor-bearing mice. All data collected were analyzed, and doublets were 
excluded by using forward scatter height and area (FSC-H/FSC-A). Live cells 
were detected by gating on PIlow cells based on the unstained control. The 
frequency of macrophages was determined by gating on Gr-1− and F4/80+ cells. 
Gating from PIlow cells, the gate for CD11c− cells was determined in comparison 
to an unstained sample. From there, IMCs were identified by the expression Gr-1 
and CD11b. The gate for IMCs was chosen in comparison to the relevant FMO.
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